We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

4,800
Open access books available

123,000
International authors and editors

140M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Treatment of the end Stage Liver Cirrhosis by Human Umbilical Cord Blood Stem Cells: Preliminary Results

Jong Yoon Bahk\textsuperscript{1*}, Zhengfu Piao\textsuperscript{2*}, Jae Hun Jung\textsuperscript{3} and Hoon Han\textsuperscript{4}

\textsuperscript{1}ChungAng University Medical School
\textsuperscript{2}Beijing You-an Hospital, affiliated Capital Medical University & Beijing Institute of Liver Disease
\textsuperscript{3}Gyeongsang National University Medical School
\textsuperscript{4}Histostem & Huenna Ltd

\textsuperscript{1}Korea
\textsuperscript{2}China

1. Introduction

The liver is a vital organ essential for life of vertebrates and other animals and plays a variety of metabolic functions, including glycogen storage, detoxification, plasma protein synthesis, the production of biochemicals for digestion and other roles. In the normal liver, hepatocytes physiologically renewed at very slow tempo. However, when injured by acute damage or drug intoxications, dormant hepatocytes re-enter the cell cycle and hepatic progenitor cells (HPCs) or oval cells are also thought to differentiate into hepatocytes, resulting in restoration of the structure and functions of the liver parenchyma (1-2): thus the liver has regenerative capacity. In severely overwhelmed cases, mature hepatocytes seemed to be blocked their proliferation activity, but HPCs are thought to be profoundly activated and play an important role in compensation of liver function (3, 4). When liver injury and inflammation occur chronically, normal liver tissue is replaced by fibrosis, scar tissue, diffuse necrosis and regenerative nodules (5), thus resulting in an irreversible chronic inflammation loss of liver function at the final stage: liver cirrhosis (LC) (6, 7, 8, 9).

Regardless of its underlying causes, the morphologic figures and complications caused by LC are similar and as disease progresses, complications develop. They include portal hypertension, varix, ascites, hepatic encephalopathy, idiopathic peritonitis and hepatic coma. The classification of LC is based on the etiology, such as alcoholics, post-hepatic, biliary, cardiac, metabolic, inherited and drug induced cirrhosis. Incidence of the specific types of liver cirrhosis is different from area to areas. Alcoholic cirrhosis is the most common type in North America, Western Europe and South America. Abstinence from alcohol would prevent the complicating liver cirrhosis (10). One-fourth of the patients with repeated liver injuries and three fourth of post-hepatic cirrhosis has the history of viral hepatitis (hepatitis B or hepatitis C). Post-hepatic cirrhosis induced by those viruses is the

\textsuperscript{*} Dr. Bahk and Dr. Piao are co-corresponding authors
most common cirrhosis found in South Eastern Asia and China including Korea, and second most common in America and Western Europe. In America, over 20% of patients infected chronically with HCV for more than 20 years were reported to develop post-hepatitic cirrhosis (11). Biliary cirrhosis also occurs in association with injury of the biliary system or its prolonged impairment, which destroys liver parenchyme with progressive fibrosis. Billary, cardiac, metabolic, inherited and drug induced liver cirrhosis are much less common than alcoholic or posthepatitic cirrhosis (12). Avoidance of causative drugs, excessive protein intake and anti-infectious medicine were usually used as a first choice of treatment. Overall, about 75% of patients have progression and die within 5 years after the findings of the disease. Immune system is also deeply involved in the magnitude of cirrhosis. For example, in some instances cirrhosis can cause immune system dysfunction, leading to high susceptibility to infections or in other cases, autoimmune responses caused by the immunologic damage to the liver causing inflammation and eventually scarring and cirrhosis.

Until now, no simple hematologic diagnostic test for the LC has been developed (13). LC is diagnosed by clinical findings, such as chronic liver disease, reduced platelet count, esophageal varix, ascitis, portal hypertension symptoms, splenomegaly and changes in hematologic parameters (14). For the definite diagnosis, the liver biopsy is used, although invasive.

LC is the common end feature of an excessive and persistent scaring resulted from secondary fibrotic tissue remodeling followed by liver injuries and is regarded as irreversible disease. In the rodents, both findings that carbon tetrachloride (CCl₄) treatment and bile duct ligation injury were reported to induce fibrogenesis (15), and spontaneous recovery from once established liver fibrosis (16-17), suggest that the hepatic fibrosis is a dynamic bi-directional event, and highlighted that the liver fibrosis is potentially reversible by antifibrotic therapy (18). After hepatic injury, the hepatic stellate cells (HSCs), positioned in the center of the ongoing fibrogenesis of liver (19), are activated to proliferate and to produce contractile elements such as smooth muscle actin (α-sma), a major determinant of sinusoidal portal hypertension (27), and collagens (mainly type I and III) (21). This process is most likely mediated through the stimulation of cytokines, such as transforming growth factor-β (TGF-β), platelet-derived growth factor (PDGF), and endothelin (ET-1) (20), that are produced in a synergistic fashion of paracrine and autocrine from injured hepatic cells and inflammatory cells. The positive feedback loops between extracellular matrix and produced cytokines may also play an important roles in the acceleration of fibrosis (22).

Among them, TGF-β1 is thought to be the most significant factor for HSCs, because it upregulates the expression of its receptor (23, 32), leading to raising the susceptibility to other mitogens such as PDGF, thrombin and angiotensin-II, etc. and eventually inducing proliferation of HSCs. It also accelerated the accumulation of HSCs in response to migration stimuli such as PDGF, vasoactive substance ET-1, and monocyte chemotactic protein (24). Extracellular matrix (ECM) modulates HSC functions by interacting it with PDGF, fibroblast growth factor (FGF), TGF-β, and matrix metalloproteinases (MMPs) that present in the space of Disse (25). Integrins expressed on HSCs play important roles in cell-matrix interactions for activation of latent TGF-β1 that modifies fibrogenesis. In contrast, basement membrane tends to suppress the proliferation activity of HSCs and their collagen synthesis (26). The cirrhotic liver overexpressed the ET-1 (28), a stimulant of nitric oxide production from HSCs and autocrine, that plays important roles for their own proliferation. HSCs also secrete neutrophil and monocyte chemoattractants, such as colony...
stimulating factors (CSF), MCP-1, and IL-8 that amplify the hepatic inflammatory response (31). Matrix synthesis is highly dependent on TGF β-1 and liver cirrhosis is closely related with ECM alteration in quantity and quality. Hepatic fibrosis is enhanced by synthesis of the neomatrix with type-1 collagen and the neomatrix degradation is inhibited by TIMPs (tissue inhibitor of metalloproteinases, TIMPs) (33). Thus activated HSCs are responsible for hepatic fibrosis. TIMP-1 inhibits apoptosis of HSCs (33) and induced promotion of perpetuation in hepatic fibrosis (34).

Prevention of the unnecessary medication is important for maintaining physiological conditions of the liver because it is very sensitive to medicines as well as microbial infection. The principle of treatment in LC is to remove such potential risk factors, and to correct the underlying invasive causes. Currently, treatments are focused on preventing complications such as ascites, esophageal varix and hepatic encephalopathy etc. Detection of serological changes at the early stage and regular follow up studies of those features are important for reducing the risky liver diseases such as LC. Usually, diet, bed rest, fluid restriction and diuretics, paracentesis and the liver transplantation are included in the treatment of the LC (35-36). For the treatment of decompensated LC, orthotopic liver transplantation is regarded as the only definitive therapeutic option (36). Several factors such as lack of available donors, combined with operative risks, complications associated with rejection, usage of immunosuppressive agents and cost-intensiveness make this strategy available to only a few people (37, 41). Those problems inherent in the liver transplantation have prompted the search for alternative therapeutic methods for intractable liver diseases (42).

Recently, along with the development of regenerative medicine, the use of pluripotent stem cells are proposed for recovering from the disease states as an alternative therapy (38). Fetal liver derived stem cells transplanted showed some improvement for conservative management in the end stage liver diseases (39). In clinical cell therapy, highly enriched cell numbers and the high repopulation potential are essential (40). Liver cells obtained from the post-mortem have been also used for transplantation as the promising alternative (43-46). The liver cell transplantation is regarded as a less invasive, less expensive, and can alleviate the problem of organ shortage. Although there are some advantages in the liver cell transplantation over the orthotopic liver transplantation, long-term observation seems to be important for the evaluation.

Reversal of hepatic fibrosis and cirrhosis may be achieved by resolution of liver fibrosis, an increase of apoptosis of activated HSCs and collagenolysis (47). In the CCl₄ rat model, the removal of CCl₄ increased the apoptosis of HSCs: 50% decrease in cell numbers at 72 hours post-removal. And antifibrotic therapy with NO donor decreased the HSCs number to 50% at 18 hours after the treatment (48). Induction of HSCs apoptosis degraded the matrix and recovered from the liver fibrogenetic conditions by removing the source of fibrotic neomatrix and TIMPs. (49-50) Biliary fibrosis was reversed after decompression of the bile duct ligation (51). Apoptosis of HSCs induces pro-MMP-2 activation (52) suggesting matrix remodeling, because MMPs specifically degrade collagens and non-collagenous substrates in matrix. The matrix degradation seems a pivotal initial step in the processes of liver fibrosis resolution. The most important event is the action of the interstitial collagenases, MMP-1, which cleaves the collagen-1 molecule (53). Collagenase activity resulted from the gap between activated MMPs to TIMPs. Increase of TIMP-1 expression occurs in parallel with progressive fibrosis. Sustained TIMP-1 expression means the failure in degradation of fibrosis and there is intrinsic link between HSC apoptosis and matrix degradation (47).
suggests that the proteolysis facilitates the resolution and repair of the injured liver (54). The failure of degradation of fibrosis by collagenase impairs HSC apoptosis to induce the delaying or blocking the hepatocyte regenerative response (54).

Recovery from the hepatic fibrosis has been reported in animal models after removal of CCl4, which is used for induction of acute hepatitis (55-61) and clinical patients (62-66). Hepatic fibrosis, induced by several toxins (57-59) or ligation of bile duct (60), was reversed after the removal of the causes. In human, reversal of the hepatic fibrosis was reported in patients with alcoholic liver disease, hemochromatosis and other liver diseases (62-64). Reversal of the posthepatic cirrhosis was also noted after improvement from the hepatitis B infection (65). Moreover, posthepatic cirrhosis due to hepatitis C infection responded to the interferon treatment (66).

Due to the limitation of the donor livers, the stem cell-based therapy has been suggested as a possible alternative therapy (67). Plasticity (trans-differentiation) and fusion activities inherent in stem cells are important for the development, regeneration and repair of liver organs (68-70, 72). The stem cells produce various humoral substances (cytokines, growth factors) and factors for homing or migration, also. Those characteristics of stem cells are also important for the therapy (71). Recently, mesenchymal stem cell (MSC) derived from umbilical cord (UC) is regarded as a promising form for cell therapy because of their easy accessibility, MSC is much primitive than other tissue sources and do not express the major histocompatibility complex (MHC) class II (HLA-DR) antigens (74). Previous studies have shown that UCMSC are still viable and not rejected at 4 months after xenografts, without the need for immune suppression, suggesting that they are a favorable cell source for transplantation (75-77). UCMSC are able to differentiate into adipocytes, osteocytes, chondrocytes (78,79), neurons (80,81), cardiomyocytes (78,82) and renal tubule epithelial cells (83) upon cultured in induction media.

Initially, stem cell was isolated from bone marrow and characterized as plastic adherent fibroblastoid cell which has the capacity to generate some tissues (84). As study on stem cell has progressed, the stem cells were also found in the many other adult organs. The discovery of trans-differentiation potential (85) led us to use them in currently incurable or intractable diseases. Stem cells are used for two purposes: one is the trans-differentiation of stem cells into the specific cell types to replace the damaged or destroyed cells or tissues, and the other is the stimulation of the pre-existing native cellular repair mechanism in damaged organs, which may contain resident dormant stem cells. Currently, stem cell-based cell therapy is increasingly applied to the variety of diseases including cardiovascular issues (86), diabetes (87), musculoskeletal disorders (88), renal problems (89), impotence (90) and hepatic cirrhosis (91). Stem cells can also be used for cytokine producer. Stem and other cells, which are genetically engineered for the production of cytokines, are also used as a vehicle of cytokines for targeting injury or disease sites, such as cancer sites (92). Stem cells, in particular committed to hepatocytes, can also be used for screening of drug toxicity (93). Stem cells are classified into three, according to the differences in sources; embryonal stem cell (ESC), adult stem cell (ASC) and induced pluripotent stem (iPS) cell. ESC was developed by Thomson in Wisconsin (94). Fetal stem cells and amniotic stem cells may belong to this category. The differentiation potential of ESCs is great but the clinical use has been strictly limited due to the ethical problem and the tumorigenesis. The iPS cells were generated from mouse fibroblasts in 2006 by Yamanaka (95), with introduction of four genes; Oct 3/4, Sox2, c-Myc, and Klf 4. The potentiality of iPS cells seems appears to be...
unlimited for clinical applications, but the bio-characterization of iPS cells has not established yet, although they are under intensive study. The origin of ASCs first discovered is bone marrows (BMSC), and then, the ASCs were discovered from the many mature organs (96-100). Among these, bone marrow, adipose tissues (ADSC) and umbilical cord blood (UCBSC) derived stem cells are currently available for cell-based clinical therapies. BMSCs were actively applied for the treatment of hematologic diseases, already. The spectrum of clinical application of BMSCs continues to expand with the time. UCBSCs are collected from venous blood of the cord, but the cell number collected is not great. The UCBSC was applied for Fanconi’s anemia (101) in 1986 between siblings. UCBSC seems to contain the most immature form of ASCs that have few chances to contact with environmental antigens, immunologically immature (102). The UCBSCs do not raises any ethical concern at umbilical cord blood collection issues and collection can be processed without invasiveness for donors. The regenerative capabilities of UCBSC are similar to other types of ASC (103). Adipose tissue derived stem cell (ADSC) was first described by plastic surgeons (104). The procedure harvesting adipose tissue is a common work among plastic surgeons for cosmetic or regenerative purposes, although it is somewhat invasive. The processed lipoaspirated tissues harbor abundant multipotent stem cells, which have similar potential with BMSC or UCBSC (103). ADSCs are permitted for autologous cell-based therapy in many countries.

The angiogenic, neurogenic and trans-differentiation potential of stem cells are the principal targets in stem cell based treatment (105-110). Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet derived growth factor AB (PDGF-AB), transforming growth factor-β (TGF-β), and integrin β are stem cell angiogenic factors (111,112). Brain-derived neurotrophic factors, and neurotrophin-4/5 (NT4/5) (113,114) are stem cell neurotrophic factors. Reports on the effects of stem cells for improvement of vascular insufficiencies (115-118) and neuropathies (119-121) are accumulating these days. Liver cirrhosis has been thought to be an irreversible disease. However, recent studies on cirrhosis of animals and humans suggest that liver cirrhosis is a potentially reversible disease. Stem cells, which are of anti-fibrotic and trans-differential potential, raised the possibility of their use for the treatment of liver fibrosis and cirrhosis as an alternative treatment replacing for liver transplantation.

In the present study we report our pre-clinical and clinical experiences of umbilical cord blood derived stem cell treatment for end stage liver cirrhosis, and discuss on the stem cell therapy in liver cirrhosis.

2. Materials and methods

2.1 Preclinical study

For the evaluation of the stem cell effect, we prepared the rat liver cirrhosis model with carbon tetrachloride (CCL4). Male Sprague-Dawley rats (6 weeks old, 180–200g) were used. The rats were grouped into 3, one control group (A) and two experimental groups, CCl4 treated group (B) and CCl4 treatment plus stem cell treated group (C). Cirrhosis was induced by intraperitoneal administration of CCl4 (4:1 olive oil) at a dose of 0.1 mL/100 g body weights, three times a week. The same volume of olive oil only was intraperitoneally infused for control. For cirrhosis induction, CCl4 was infused for 8 weeks. Human umbilical cord blood stem cells were infused at a dose of 1x10^6 cells in 0.2 mL through the tail vein, and saline of same volume for control and CCl4 only group. Rats were sacrificed at one, two
and four weeks and one pathologist evaluated the pathologic changes of liver. For pathologic evaluation, sections of approximately 4 μm thick were made and stained with haematoxylin and eosin (H&E) staining for routine histology, and Masson’s trichrome (MT) staining for collagen.

2.2 Clinical study
Total 51 patients were participated in this treatment. The exclusion criteria for patient recruitment in stem cell treatment with liver cirrhosis were age limitation, over 70, and cancer. Among them, 46 patients (male 27 and 19 female) were classified as the Child-Pugh (CP) class C liver cirrhosis and 5 (four male and one female) were classified as the CP class B, finally, although they were classified as the class C from the other hospital, at the time of initiation. All participants are randomly involved in this treatment after reviewed the medical records of patients whose life expectancy were less than 6 months, evaluated by doctors in charge before involved in these treatments. 43 patients graduated from the college or upper rank school. The cause of cirrhosis was alcoholic in 18 and posthepatitic in 36. Although 17 had the heart problem, it was not definite whether cardiac problem was the solitary cause of the cirrhosis or not, except two. The common clinical complications for portal hypertension were varix (41) and ascitis (34). For all patients, the explanation was made on the treatments rationale and material, and informed consents were obtained. All patients understood the treatment and no body has the opinion on baseline studies (Table 1). All participating patients were negative on cancer especially at baseline studies. They had specific conditions that could be related with liver cirrhosis and had the several complications induced from portal hypertension (Table 2).

| Imaging          | Ultrasound Exam. on Heart, Liver, Kidney CT on Abdomen |
|------------------|--------------------------------------------------------|
| Endoscopic       | Gastroscopy, Esophagoscopy                             |
| Blood & Serology | CBC, Serologic series 12                              |
| Urine            | UA, Microscopic Examination                           |
| Cancer Marker    | AFP, CEA                                               |
| Others           | VDRL, AIDS, Hepatitis B Ag/Ab, Hepatitis C AG/Ab, Electrolyte, C-reactive protein, ASO titer, EKG, ESR, RA factor |
| Coagulation      | PT (INR)                                               |

Table 1. Base line studies.

The human umbilical cord blood stem cells (hUCBSC) were supplied by Histostem Co. Ltd. (Seoul, Korea) that was permitted for clinical use from the Korean government (KFDA). The supplied stem cells were ABO, HLA-ABC, DR and sex matched for each patient, and the donor of each stem cell unit does not have any specific familial medical history. The stem cell markers of hUCBSCs were studies by flow cytometry. Total cell numbers that infused for each patient were around $1.5 \times 10^7$. hUCBSCs were infused percutaneous directly into liver parenchyma using needle under the ultrasonographic guide. All patients
were informed for usual life after one-day bed rest. Patients were followed every month from treatment at least for 6 times. At follow up check, patients were evaluated for prothrombin time, albumin, ascities and encephalopathy before and after each month from the stem cell therapy. Patients were evaluated for serological results, ascities and encephalopathy before and after each month from the stem cell therapy. The final survival was checked at November 30, 2010, 7 to 75 months from the initiation of the stem cell therapy.

| Conditions manifested at initial visit | Positive Patients Number | Negative Patients Number |
|---------------------------------------|--------------------------|--------------------------|
| Alcohol Intoxication                   | 18                       | 33                       |
| Hepatitis History                      | 36                       | 15                       |
| Heart Problem                          | 17                       | 34                       |
| GB Problem                             | 0                        | 51                       |
| Varix                                  | 41                       | 10                       |
| Ascitis                                | 34                       | 17                       |
| Hepatic encephalopathy                 | 19                       | 32                       |
| Peritonitis                            | 1                        | 50                       |

Table 2. Patient condition at presentation.

| Study Items                  | Normal Value | Normal Patients | Range of Measure value | Patients Number |
|------------------------------|--------------|-----------------|------------------------|----------------|
| Total Protein                | 6.3 - 8.2 g/dL | 12              | 1.0 - 2.0 | 2.1 - 3.0 | >3.1 | 39 |
| Albumin                      | 3.5 - 5.1 g/dL | 5               | 17            | 26            | 3  |
| ALP                          | 38 - 126      | 13              | 38            | 49            |    |
| sGOT                         | 5 – 40 IU/L   | 2               | 50            |               |    |
| sGPT                         | 5 – 35 IU/L   | 1               |               |               |    |
| Total Bilirubin              | 0.2 - 1.3 mg/dL | 14             | <2mg/dL  | 2-3mg/dL  | >3mg/dL | 18  |
| Direct Bilirubin             | 0 - 0.3 mg/dL | 17              | 18            | 16            | 3  |
| PT (INR)                     | <1.7          | 18              | <1.7         | 1.7 - 2.3    | >2.3 | 11  |

Table 3. The results of serologic test before stem cell treatment.
3. Results

3.1 Stem cells

The flow cytometric results (Figure 1) of hUCBSCs were CD13(+), CD14(-), CD29(+), CD31(-), CD34(-), CD44(+), CD45(-), CD49e(+), CD54(+), CD90(+), CD106(-), AMSA(+), SH2(+), SH3(+), HLA-ABC(+) and HLA-DR(-).
3.2 Preclinical study
The gross finding of the liver was examined (Figure 2) at 12 weeks after the starting the infusion of CCl₄. Compared to the control which have normal hepatic configuration (A), the CCl₄ infused rats (B) without stem cell treatment showed nodular surfaced distorted liver but CCl₄ infusion with stem cell treatment rat (C) showed recovered from the distorted nodular liver but much distorted compared with control (A).

The microscopic study (Figure 3), with haematoxylin and eosin (H&E) staining for routine histology and Masson’s trichrome (MT) staining for collagen, were done on liver section at 1, 2 and 4 weeks after CCl₄ injection for 8 weeks. The control group showed normal

![Fig. 1. Flow cytometric findings of the surface markers in hUCBSCs.](image)

![Fig. 2. Gross findings of the liver at 12 weeks after initiation of the CCl₄ intraperitoneal injections. A is control, B is CCl₄ intraperitoneal injection and C is CCl₄ intraperitoneal injection plus hUCBSC treated rat.](image)
architecture at all livers (A). At 1 week after CCl₄ injection for 8 weeks, the experimental group showed the cirrhosis was induced in both without (B1) and with stem cell treatment group (C1), the fibrosis and deposition of collagen, separating liver parenchyma into large lobules. At 2 week after CCl₄ injection for 8 weeks, there was definite difference between without stem cell treatment group and with stem cell group. The without stem cell treatment group (B2) showed increased septa composed of fibrosis and collagen. Compared to without stem cell group, with stem cell group (C2) showed reduced septa than first week after CCl₄ injection for 8 weeks. At 4 week after CCl₄ injection for 8 weeks, the without stem cell treatment group (B3) showed much increased septa composed of fibrosis and collagen and there is new fine septa were appeared within large lobules. In with stem cell treatment group (C3), the septa composed of fibrosis and collagen were reduced and the lobules are closely approximated each other. In these pathologic findings, experimental group without stem cell therapy induced the extensive fibrosis / cirrhosis and the fibrosis was progressed as the time passing (B). These CCl₄ induced fibrosis / cirrhosis was proved by disruption of liver parenchyma architecture, extension of fibers, large fibrous septa formation, pseudolobe separation and collagen accumulation. These alterations were progressed and increased in fibrosis and collagen deposition with time passing. The histopathological findings confirmed that the cirrhosis was significantly reduced by stem cell infusion.

Fig. 3. Microscopic findings of the rat liver in control and experimental rats. A from control rat, B from CCl₄ intraperitoneal injection only rat and C from CCl₄ intraperitoneal injection with hUCBSC therapy rat. 1 at 9 week from CCl₄ intraperitoneal injection, 2 at 10 weeks and 3 at 12 weeks.
3.3 Clinical study
The participants’ age ranged from 49 to 68 years old (mean 54.7 years). The mean age of the CP class C were 56.2 and class B were 48.9. After the stem cell therapy, there was no death within 6 months from the initiation of the stem cell therapy. There were 9 deaths from 7 months within 12 months, 19 deaths from 13 months within 2 years, 13 deaths over 2 year within 3 years, 3 deaths over 3 years within 5 years. 7 are living now, from 11 to 75 months from stem cell therapy, and among them, two are living over 5 year. During the procedure (Figure 4), the bleeding from the liver was not remarkable. Clinically, ascitis was improved in 21 and 5 did not show any ascitis within 6 months. Among 5, 2 are alive more than 5 years (Figure 5). In hepatic encephalopathy, all patients showed improvement in symptom. But there is no patient who lived more than 30 months. Serologic follow up check was done in all patients (Table 3 and 4). In serologic test, although there were some changes in the

Fig. 4. Laparascopic view of percutaneous injection of the stem cells into liver. The needle is inserted into the nodular surfaced liver.
Fig. 5. CT findings from the patient who is living more than 5 years. A is CT taken just before (Feb. 21, 2005) stem cell therapy and B is CT taken was after 5 months (July 23, 2005). The measured liver size was increased from 689.98 CC to 915.36 CC and hepatic density is lowered suggesting release of fibrosis.
results, it was impossible to get the uniform information in trends of change. Among 39, those who had abnormal protein level, total protein level was normalized at 6, but among 39, only 2 were normalized in albumin. In these 2, one had normalization of total protein level but one did not, meaning some difference in improvements among sub-group.

| Study Items     | Normal Value | Normal Patients | Range of Measure value | Patients Number |
|-----------------|--------------|-----------------|------------------------|----------------|
| Total Protein   | 6.3 - 8.2    | 18(+6)          | 1.0 - 2.0              | 33(-6)         |
|                 |              |                 | 2.1 - 3.0              |                |
|                 |              |                 | >3.1                   |                |
|                 |              |                 | 12(-5)                 |                |
|                 |              |                 | 25(-1)                 |                |
|                 |              |                 | 7(+4)                  |                |
| Albumin         | 3.5 - 5.1    | 7(+2)           |                        |                |
| ALP             | 38 - 126     | 17(+4)          |                        | 34(-4)         |
| sGOT M: 17 - 59 | 9(+7)        | 42(-7)          |                        |                |
| F: 14 - 36      |              |                 |                        |                |
| sGPT M: 21 - 72 | 12(+11)      | 39(-11)         |                        |                |
| F: 9 - 52       |              |                 |                        |                |
| Total Bilirubin | 0.2 - 1.3    | 16(+2)          | <2mg/dL                | 21(+3)         |
|                 |              |                 | 2-3mg/dL               | 14(-2)         |
|                 |              |                 | >3mg/dL                | 0(-3)          |
| Direct Bilirubin| 0 - 0.3      | 18(+1)          |                        | 33(-1)         |
| PT (INR)        | <1.7         | 23(+5)          | <1.7                   | 21(+3)         |
|                 |              |                 | 1.7 - 2.3              | 14(-2)         |
|                 |              |                 | >2.3                   | 0(-3)          |
|                 |              |                 | 23                     |                |
|                 |              |                 | 22                     |                |
|                 |              |                 | 6                      |                |

Table 4. Serologic test results at post stem cell treatment 6 months.

4. Discussion

Most of the chronic liver injuries, regardless of their causes, progress to liver fibrosis and eventually result in cirrhosis that is thought to be irreversible, and the liver cirrhosis (LC) results in impairment of the hepatic function becoming a massive health care burden worldwide. LC is induced by many different causes, such as chronic viral hepatitis, toxic damage including alcohol, parasitic disease, inborn errors of metabolism, and non-alcoholic fatty liver disease etc. The cause of LC has a wide geographic variation. Alcohol is the most common cause in western countries (122) and liver disease is the 5th most common cause of death in the United Kingdom (123.) Recent reports on pre-clinical and clinical studies suggested that LC could be reversible. HSCs activated upon liver injury are thought to be responsible for collagenogenesis and fibrosis in extracellular matrix (124, 125). Modulation of HSC activity (126,), promotion of HSC apoptosis (127), blocking of matrix formation (128) or anti-proliferation measures on matrix fibrogenic and contractile response to HSC and degradation of established matrix (125,129) could be taken as potent strategies for reversal of LC. In addition to these strategies, stem cell therapy with multiple cytokine production and trans-differentiation potential would be a new option (130) for reversal of established LC. HSCs are responsible for the production of extracellular matrix at the center of LC. Therefore, the inhibition of the activation of HSCs (131-133) or promotion of HSC apoptosis

www.intechopen.com
would be an eradicating measure for fibrogenesis. The platelet-derived growth factor (PDGF) is the most potent mitogen for HSCs, thereby inhibitors against PDGF have been tried (136-138). For the patients whose fibrosis is progressing, the matrix formation blockers (139) or anti-proliferation measures to matrix fibrogenesis (140) would be another measure for the reduction of LC. HSCs contribute to portal hypertension through multiple mechanisms including collagen deposition, vasoconstriction, and regulation of sinusoidal structure. So, the reduction of contractile response to HSC (141) would be a measure reducing critical complications induced by portal hypertension. Increasing the degradation of established matrix (125,142,142) would be an ideal strategy for reversal of LC.

Recently developed stem cell therapy (143-144) may be a promising strategy for LC, because we can expect them to trans-differentiate into hepatocytes and to stimulate the differentiation of hepatocytes from the dormant stem cells remaining in injured host liver and stem cells in bone marrow through cytokine production (145). BMSC, ADSC, and UCBSC are currently used for stem cells therapy. Unseparated bone marrow cells and purified BMSCs have been used for the treatment of the hematopoietic diseases for more than 50 years. Their application fields are expanding day by day. For advanced liver diseases such as cirrhosis, stem cell engraftment can be most promising strategy after the organ transplantation (146). In animals treated with CCl₄ intraperitoneal infusion, the percentage of lin- Sca-1+ cells in the bone marrow and peripheral blood increases twofold at twenty-four hours later (147) and this increase peaks at day one in the bone marrow and day two in the peripheral blood (147). This finding suggests that bone stem cells started to proliferate and migrate to the periphery (147). Requirement of engraftment of stem cells into the patients with the severe liver diseases are increasing. For BMSC therapy, bone marrow aspiration is inevitable and bone marrow aspiration is an invasive procedure. Differentiation potential, and maximal life span of BMSC decrease with increasing age (148-149). In post-hepatic LC patients, the autologous BMSCs are not suitable for the treatment, because their proliferation capacity is restricted significantly in the tissue environment of end stage of the disease (150).

ADSCs were relatively recently found. Their easy isolation (151) and high differentiation potential (152) may be attractive as alternative promising stem cells in place of BMSCs. In the meantime, UCBSCs has been used for several diseases. UCBSCs have advantages over other types of stem cells, because umbilical cord blood (UCB) can be obtained without invasiveness or harm to donor. Cells from UCB have many advantages because of the immaturity of stem cells compared to other types. Moreover, UCBSCs provide no ethical barriers for basic and clinical applications (153-154). Recently, UCB banking for transplantation of haematopoietic stem cells is increasingly in many institutions (155) due to their easy availability and the ready on shelf system. All clinical papers are of autologous or allogenic stem cell therapy. Among the adult stem cells, UCBSCs are youngest stem cells and they had only few chances to contact with environmental antigens. UCBSCs have higher proliferative potential than BMSC and higher expression of the endothelial-specific markers following endothelial differentiation (156).

When we decided to attempt to treat with UCBSCs for some diseases, we carefully consider suitable cell (origin) for target organs, cell numbers, route for administration, supplementation of growth factors and post-treatment cares. In spite of increasing requirement of stem cell treatment, the protocol for stem cell treatment has not established until now. Because the preparation of the stem cells for enough quantity that has the identical or similar biology is not easy, we should consider the measure to secure the
enough number of stem cells, culture or mixing of different donors. Although many trials with stem cell were done, most of them are autologous rather than allogenic. Basically, many diseases caused by different pathogenesis, it needs different treatment. In case of LC, bone marrow stem cells from liver cirrhotic caused by chronic hepatitis B infection showed significantly lower S-phase fractions and growth factor (IGF-1, PDGF α, PDGF β) receptor expression than normal people (157). It indicates that allogenic stem cell therapy is better than autologous in LC. We suppose that allogenic stem cell therapy would be reasonable in case of the hereditary or genetic disease. The number of stem cells in specific treatment has not decided yet, too. Moriya et al. (158) used 1x10⁵ embryonal stem cells in animal study model (mice). Liu et al. (159) used 5x10⁵ endothelial precursor cells in 150 g animal study model (rat). Yan et al. (160) infuse 3x10⁶ human UCBCs in mice. Although these reports are animal study, when we calculate the cell number in weight to weight (animal to human) base, the cell number for human treatment should be over 1x10⁸ cells. But Mohamadnejad et al. (161) infused 31.73 x 10⁶ autologous bone marrow mesenchymal stem cells for four liver cirrhotic patients via peripheral vein. So, the cell number for treatment of disease should be standardized according to the disease, although there should be many trials for standardization.

In introduction part of this chapter, we mentioned on the characteristics of stem cells, homing or migration (someone uses ‘targeting’). Homing in stem cell biology means stem cell moving toward injury site along the some chemotactic signal (162). So, many animal experiments localized the targeted stem cells, which were infused via tail vein (260-164) or intraperitoneal infusion (165) and sometimes via specific route such as portal vein (166). And in case of cellular cardioplasty for myocardiac infarction model, several different infusion has been used, direct intracoronary (167), intravenous with homing (168) and mobilization with homing from bone marrow or peripheral blood (169). In cellular cardiomyoplasty, according to the cell delivery system, the results are different. Least effective method is mobilization from peripheral blood or bone marrow (170-171) and most effective method is intracoronary infusion (172-173). And in case of intravenous infusion, according to the blood flow, all blood in body has to pass the lung and some proportion of infused stem cells are trapped at the lung (174-175). Some are trapped at other organs (176).

There are many growth factors which support or enhancing stem cell activities. The supplement of growth factors into stem cell culture media or coupled treatment of stem cell with growth factors was reported in vitro and in vivo, already. Supplement of growth factors in culture system has been done from long ago in culturing technique and sometimes essential job for culture, but the coupled clinical treatment of stem cell with growth factors (177-178) are in different conditions (177-178). Although we use the various growth factors for in vitro culture system, there are a few growth factors which are permitted to use for human from the health concerning governmental bureau. So, it is not easy to search the simultaneous application of the growth factor as an auxiliary measure for stem cell therapy (178-180).

Post-treatment care are difficult to mention at present time because there is no report for large sized world wide data related on the stem cell treatment on specific disease until now. Although the data on the post-treatment care for better maintenance of end result of stem cell therapy are needed, it is not proposed yet. As in the material and method, we had the clinical treatment for end-stage LC whose survival was expected to be less than 6 months. The result showed that the all patients had improved survival although their initial life expectancy was based on the doctor’s experiences. Other laboratory data had some
differences among patient to patient, but most of the patients who had the hepatic encephalopathy and more than half of the ascitic patient had the improved symptoms.

In author's stem cell treatment for LC, we used umbilical cord blood stem cells (UCBSCs), only. UCBSCs produce and secrete various humoral factors (cytokine or growth factors)\(^{(261-262)}\). They are stem cell factor (SCF), macrophage colony stimulating factor (M-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), vascular endothelial growth factor (VEGF), interleukin 1\(\beta\) (IL-1\(\beta\)), IL-6, IL-8, IL-11, IL-12, IL-15, stromal cell-derived factor 1\(\alpha\) (SDF-1\(\alpha\)), hepatocyte growth factor (HGF), epithelial cell-derived protein 78 (ENA-78), Growth-related oncogene (GRO), oncostain M (OSM), monocyte chemotactic protein-1 (MCP-1), fibroblast growth factor 4 (FGF-4), FGF-7, FGF-9, granulocyte chemotactic protein 2 (GCP-2), Insulin like growth factor (IGF), Insulin-like growth factor binding protein 1 (IGFBP-1), IGFBP-2, IGFBP-3, IGFBP-4, Interferon-gamma-inducible protein 10 (IP-10), Leukemia inhibitory factor (LIF), migration inhibitory factor (MIF), macrophage inflammatory protein 3\(\alpha\) (MIP-3\(\alpha\)), osteoprotegerin, (OPG), pulmonary and activation-regulated chemokine (PARC), Placenta growth factor (PIGF), transforming growth factor \(\beta1\) (TGF-\(\beta1\)), TGF-\(\beta2\), TGF-\(\beta3\), tissue inhibitors of matrix metalloproteinases 1 (TIMP-1) and TIMP-2.

Among these cytokines, some of them are favorable for antifibrosis and some are prone to enhance the fibrosis in liver. The results of balance between favorable and unfavorable effects among the various cytokines secreted from the UCBSC would predict treatment or aggravation of LC. Among above cytokines that UCBSCs secrete, HGF, IGF-1, IGFBP and interferon would be closely related with fibrolysis of liver but TGF-\(\beta1\) and TIMP will promote hepatic fibrosis. Although the results of UCBSC treatment on LC patient showed much improvement on symptoms and liver function related laboratory data, we do not know the interaction between those cytokines, which has some antagonistic effects.

We injected stem cells into liver parenchyma directly under the ultrasound guide. Total cell numbers were around 1.5 \(\times\) 10\(^7\) hUCBSCs in each patient. Until now, there are many trials with animal model of LC but no author has presented the proper cell number for stem cell treatment on LC. Around 1 \(\times\) 10\(^6\) cells were infused intravascularly in rat or mouse liver cirrhosis model and they showed improvement in hepatic functions. Although the most of patients in our treatment group showed favorable effects on LC after stem cell therapy, the role of cell number in LC treatment was not definite. We infused the stem cells directly into the target organ, liver, the cell number that authors used were much less than animal experiments. In spite of our small numbered stem cells, there was some improvement in data for hepatic function.

As mentioned before, we infused the stem cells directly into the liver parenchyma. The infusion route would be closely related with results of the stem cell treatment. In systemic intravenous administration would be the easiest method in stem cell treatment but the trapping of stem cell by lung or some reticuloendothelial system, during circulation before homing, would lessen the treatment effects. Although there are several data related with homing after intravenous infusion of stem cells, it is unclear that how many portions of infused cells are homed. To increase the homed stem cells in target organ, some therapies try to infuse the stem cells via selective artery, although it is invasive. More invasive therapy would be the orthotopic infusion/transplantation of stem cells under direct of indirect visualization. Surgically exposed target lesion would be treated with high accuracy and possibly permit reduced numbered stem cell implantation with same effects. Modern developed imaging modalities enabled us target the lesions with very high accuracy with
less damage. The choice of the route for best effective targeting the lesion would be depend on the imaging modality and technique of operator. Average life expectancy of the LC patients chose randomly by authors is expected to no more than 6 months. After stem cell therapy, no body had gone within 6 month and two of 51 patients survived more than 5 years. There would be many causes contributing to the improvement of patients' survival. Among them, the role of stem cell for improvement of survival and laboratory data should get attention. Although Kögl and Liu reported the various cytokines, which they detected from UCBCs, there would be many unknown cytokines (humoral factors), which is secreted by the UCBCs. We do not know the mechanisms that improved survival and laboratory data in liver function, but the HGF, INF and IGF and IGFBP would be closely related with fibrolysis and collagenolysis. Originally HGF has mitogenic, motogenic, morphogenic and anti-cell death activities (181), and identified and cloned as a mitogen protein for hepatocyte (182-183). HGF stimulates expression and activity of proteases involved in breakdown of ECM proteins, including urokinase-type plasminogen activator and matrix metalloproteinases. In LC, HGF suppress the proliferation while promoting apoptosis of $\alpha$-SMA-positive cells in the liver, that histological resolution from liver cirrhosis.(181) Growth inhibition and promotion of apoptosis in portal myofibroblasts by HGF would be an ancillary resolution for liver fibrosis/cirrhosis.(184) Mesenchymal stem cells (MSCs) can prevent the development of liver fibrosis, and hepatocyte growth factor (HGF) can also attenuate liver cirrhosis. (185) HGF/MSCs significantly inhibit the formation of liver fibrosis in rats, while MSCs and HGF had synergistic effects in the process. The antifibrosis effect of HGF/MSCs may have contributed in modulating the activation and apoptosis of HSCs, elevating the rHGF expression level, and decreasing the TGF-beta 1 secretion of activated HSCs.(185). In CCl4-induced liver cirrhosis rat model, hBMSCs treatment results were induced by two mechanisms that work together: the differentiation of transplanted hBMSCs into liver cells that are able to restore normal liver functions, and expression by production of MMP by hBMSCs which is involved in the repair of liver fibrosis. (186).

In interferon, there are many subtypes but only a few of them are reported to be produced from the UCBCs. Among them, interferon alpha (IFN-$\alpha$) suppress the progression of hepatic fibrosis (187), and lowers fibrosis scores, tissue hydroxyproline levels, liver TIMP-1 and elevate MMP-13 levels. IFN-$\alpha$ has role to increases HSC apoptosis, too.(188). TIMP is the representative fibrosis favoring molecule and MMP is the representative molecule for fibrolysis. IFNy have the hepatic protective effect by inhibition of adenosine A2A receptor function in hepatic stellate cells (191). Among those cytokines, M-CSF promotes the interferone production. Insulin-like growth factor-1 (IGF-1) and major portion of the circulating IGF-1 synthesized in the liver are hepatic origin in normal state, but in LC the plasma levels are diminished (190-191). When the deficient IGF-1 in LC was replaced by daily administration of recombinant IGF-1, it induces a significant improvement of liver function (192). In liver, the expression of IGF-1 receptor is poor (193-194) and it seems that IGF-1 acts on nonparenchymal cells. IGF-1 improves the liver structures and function through the activation of tissue-repair mechanism at non-parenchyma. It seems that there is an amplification loop which are favoring the efficacy of the therapy because the IGF-1 upregulate the IGF-1R in hepatic septa (195). In liver cirrhosis, the supplementation of IGF-1 induces the antifibrogenic and hepatoprotective effects. (196) Aside from the antifibrogenic effects, patients treated with stem cell showed improved serum albumin and enzyme levels indicating liver functions and these results are supposed due to IGF effects.
This discussion reviewed the mechanisms that stem cells have favoring results related with LC. But it would not be the total mechanisms that explain the favoring effect of stem cells on LC. Among the above mentioned cytokines produced by UCBSCs, there are reports for characterization of cytokines, such as SDF-1 (197), IL-8 (198), M-CSF (199), RANTES (200), MIP-1α (201), IP-10 (202), and EGF (203), but the most of them are not directly related with improvement of LC.

Until now, there are several clinical papers, around 10, on the results of autologous stem cell treatments, either autologous bone marrow derived stem cells or mobilized stem cells and fetal stem cell for the end stage liver cirrhotic patients. All of them are backing further clinical application of stem cell on liver cirrhosis. Most of the reports were related with the treatment with small number of patients, less than 10 patients, except for India (204). And the routes of stem cell infusion, aside from the mobilized hematopoietic stem cells, are portal vein or hepatic artery with a few intravenous infusions. With these data, it is practically difficult to compare the superiority of the route of stem cell infusion due to small patient number in each case. Although there are common findings are improvement of hepatic conditions.

In the clinical data that we introduced in this chapter, all patients were supposed to be gone within 6 months before they were involved in stem cell therapy, meaning terminal state LC patients. Two third in 51 had the ascitis and more than one third had the hepatic encephalopathy. After single stem cell therapy using UCBSC, most of the hepatic encephalopathy patients and more than two third of ascitic patients were improved in symptom or responded to medical therapy who were refractory to previous therapy. But other data for liver function, albumin, aminotransferases, bilirubin or prothrombin time has irregular responses. About half of patients of ascites who had the improved symptoms showed improved albumin values but difficult to pull out any reproducible protocol, requiring further study. Because we choose the patients randomly in loose exclusion criteria, it would be difficult to get the objectively reproducible data from our experience for base of any protocol in stem cell therapy. But we can get some idea of trends of stem cell therapy for LC, although we had a single treatment. The stem cell therapy improves the ascitis and hepatic encephalopathy definitely in some group of patient, although we do not characterized this group, yet. In case of hepatic encephalopathy, the most of patients showed objectively improved symptom but we do not presume the mechanism, too. At the point of patient survival, all patients survived more than 6 months, although it would be difficult to believe the patients' initial life expectancy as the objective data. The patients' survival would not be related with liver function only but would be the summation of the various indexes of life signs. The most common side reaction that related with the stem cell treatment was pain, experiencing during stem cell infusion procedures. As mentioned before, much of the stem cell biology including producing cytokines has been proven already but it would be a tip of iceberg. We treated the patients who were regarded as the hopeless condition in point of survival improvement based on the reasonable solid animal study results of stem cell therapy, but they lack objective clinical efficacy aside from trend of stem cell therapy. So, to get the further acquisition of objective clinical effects and base on proper protocol, large multicenter trial on stem cell therapy for liver cirrhosis would be needed.

5. Conclusion

The conclusion of our review and experience is that there are lots of beneficial effects of stem cells on end stage liver cirrhosis and stem cell therapy serves for prolongation of the life and
improvement of quality of life. The analysis of author’s experience lacks objectivity. And if there is the more systemic multicenter large numbered study, we can make the proper guideline for stem cell therapy on liver cirrhosis.

6. References

[1] Heim D, Wege H. (2009) Hepatic stem and progenitor cells in liver diseases and hepatocarcinogenesis. Minerva Gastroenterol Dietol. 55(2):111-210, ISSN1827-1642.
[2] Kung JW, Forbes SJ. (2009) Stem cells and liver repair. Curr Opin Biotechnol. 20(5):568-74, ISSN 0958-1669.
[3] Bird TG, Lorenzini S, Forbes SJ. (2008 ) Activation of stem cells in hepatic diseases. Cell Tissue Res. 331(1):283-300, ISSN 0302-766X.
[4] Heim D, Wege H. (2009) Hepatic stem and progenitor cells in liver diseases and hepatocarcinogenesis. Minerva Gastroenterol Dietol. 55(2):111-121, ISSN 1121-421X.
[5] Manuelpallai U, Tchongue J, Lourensz D, Vaghjiani V, Samuel CS, Liu A, Williams ED, Sievert W. (2010) Transplantation of Human Amnion Epithelial Cells Reduces Fibrosis in Immunocompetent CCI Treated Mice. Cell Transplant. 19(9):1157-68, ISSN 0963-6897.
[6] Friedman, SL. (2003) Liver fibrosis - from bench to bedside. J. Hepatol. 38(Suppl. 1):S38–S53, ISSN 0168-8278.
[7] Tasci I, Mas MR, Vural SA, Comert B, Alcigir G, Serdar M, Mas N, Isik AT, Ates Y. (2006) Rat liver fibrosis regresses better with pegylated interferon alpha2b and ursodeoxycholic acid treatments than spontaneous recovery. Liver Int. 26(2):261-268, ISSN 1478-3223.
[8] Lefton HB, Rosa A, Cohen M. (2009) Diagnosis and epidemiology of cirrhosis. Med Clin North Am. Jul;93(4):787-99, vii, ISSN 0025-7125.
[9] Fernández M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. (2009) Angiogenesis in liver disease. J Hepatol. 50(3):604-20, ISSN 0168-8278.
[10] Sandahl TD, Jepsen P, Thomsen KL, Vilstrup H. Incidence and mortality of alcoholic hepatitis in Denmark 1999-2008: A nationwide population based cohort study. J Hepatol. 2011 Apr;54(4):760-764, ISSN 0168-8278.
[11] Seeff LB. (2002) Natural history of chronic hepatitis C. Hepatology 36(5 suppl 1):S35–S46, ISSN 0270-9139.
[12] Wallaert B, Bonniere P, Prin L, Cortot A, Tonnel AB, Voisin C. (1986) Primary biliary cirrhosis. Subclinical inflammatory alveolitis in patients with normal chest roentgenograms. Chest. 90(6):842-8 ISSN 0012-3692.
[13] Oh S, Afshal NH. (2001) Hepatic fibrosis: are any of the serum markers useful? Curr Gastroenterol Rep. 3(1):12-18, ISSN 1522-8037.
[14] Lu LG, Zeng MD, Mao YM, Li QJ, Qiu DK, Fang JY, Cao AP, Wan MB, Li CZ, Ye J, Cai X, Chen CW, Wang JY, Wu SM, Zhu JS, Zhou XQ. (2003) Relationship between clinical and pathologic findings in patients with chronic liver diseases. World J Gastroenterol. 9(12):2796-2800, ISSN 1007-9327.
[15] Chang ML, Yeh CT, Chang PY, Chen JC. (2005) Comparison of murine cirrhosis models induced by hepatotoxin administration and common bile duct ligation. World J Gastroenterol. 21(11):4167-72. ISSN 1007-9327.
[16] Issa R, Williams E, Trim N, Kendall T, Arthur MJ, Reichen J, Benyon RC, Iredale JP. (2001) Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut. 48(4):548-57. ISSN 0017-5749.
[17] Issa R, Zhou X, Constandinou CM, Fallowfield J, Millward-Sadler H, Gaca MD, Sands E, Suliman I, Trim N, Knorr A, Arthur MJ, Benyon RC, Iredale JP. (2004) Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology. 126(7):1795-1808. ISSN 0016-5085.

[18] Tasci I, Mas MR, Vural SA, Deveci S, Comert B, Alcigir G, Mas N, Akay C, Bozdaiy M, Yurdaydin C, Bozkaya H, Uzunalimoglu O, Isik AT, Said HM. (2007) Pegylated interferon-alpha plus taurine in treatment of rat liver fibrosis. World J Gastroenterol. 21;13(23):3237-44. ISSN 1007-9327.

[19] Friedman, S.L. (1993) Seminar in medicine of the Beth Islael Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 328, 1828-1835. ISSN 0028-4793.

[20] Geremias AT, Carvalho MA, Borojevic R, Monteiro AN. (2004) TGF beta1 and PDGF AA override collagen type I inhibition of proliferation in human liver connective tissue cells. BMC Gastroenterol. Dec 3;4:30. ISSN 1471-230X.

[21] Kharbanda KK, Rogers DD 2nd, Wyatt TA, Sorrell MF, Tuma DJ. (2004) Transforming growth factor-beta induces contraction of activated hepatic stellate cells. J Hepatol. 41(1):60-6. ISSN 0168-8278.

[22] Parsons CJ, Takashima M, Rippe RA. (2007) Molecular mechanisms of hepatic fibrogenesis. J Gastroenterol Hepatol. 22 Suppl 1:S79-84. ISSN 0815-9319.

[23] Dooley S, Delvoye B, Lahme B, Mangasser-Stephan K, Gressner AM. (2000) Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. Hepatology. 31(5):1094-106. ISSN 0270-9139.

[24] Chang YZ, Yang L, Yang CQ. (2008) Migration of hepatic stellate cells in fibrotic microenvironment of diseased liver model. Hepatobiliary Pancreat Dis Int. 7(4):401-5. ISSN 1499-3872.

[25] Friedman SL. (2003) Liver fibrosis – from bench to bedside. J Hepatol 38:S38–53, ISSN 0168-8278.

[26] Jesnowski R, Fürst D, Ringel J, Chen Y, Schrödel A, Kleeff J, Kolb A, Schareck WD, Löhr M. (2005) Immortalization of pancreatic stellate cells as an in vitro model of pancreatic fibrosis: deactivation is induced by matrigel and N-acetylcysteine. Lab Invest. 85(10):1276-91, ISSN 0023-6837.

[27] Rockey DC. (2001) Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin Liver Dis. 21(3):337-49. ISSN 0272-8087.

[28] Pinzani M, Milani S, De Franco R, Grappone C, Caligiuri A, Gentilini A, Tosti-Guerra C, Maggi M, Failli P, Ruocco C, Gentilini P. (1996) Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology. 110(2):534-48. ISSN 0016-5085.

[29] Rockey DC, Chung JJ. (1998) Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology. 114(2):344-51. ISSN 0016-5085.

[30] Pinzani M, Marra F. (2003) Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis. 21(3):337-416. ISSN 0272-8087.

[31] Marra F. (1999) Hepatic stellate cells and the regulation of liver inflammation. J Hepatol. 31(6):1120-30. ISSN 0168-8278.

[32] Friedman SL. (2000) Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 275(4):2247-50. ISSN 0021-9258.
[33] Iredale JP, Benyon RC, Arthur MJ, Ferris WF, Alcolado R, Winwood PJ, Clark N, Murphy G. (1996) Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology. 24(1):176-84. ISSN 0270-9139

[34] Murphy FR, Issa R, Zhou X, Ratnarajah S, Nagase H, Arthur MJ, Benyon C, Iredale JP. (2002) Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem. 29;277(13):11069-76, ISSN 0021-9258.

[35] Schouten J, Michaelsen PF. (2007) Treatment of cirrhotic ascites. Acta Gastroenterol Belg. 70(2):217-22. ISSN 0001-5644

[36] Heidelbaugh JJ, Sherbondy M. (2006) Cirrhosis and chronic liver failure: part II. Complications and treatment. Am Fam Physician. 74(5):767-76, 0002-838X.

[37] Zhao Q, Ren H, Zhu D, Han Z. (2009) Stem/progenitor cells in liver injury repair and regeneration. Biol Cell. 101(10):357-71, ISSN 0248-4900.

[38] Kharazhi P, Hellström PM, Noorinayer B, Farzaneh F, Aghajani K, Jafari F, Telkabadi M, Atashi A, Hanboost M, Zali MR, Soleimani M. (2009) Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol. 21(10):1199-205. ISSN 0954-691X

[39] Khan AA, Shaik MV, Parveen N, Rajendra Prasad A, Aleem MA, Habeeb MA, Srinivas G, Raj TA, Tiwari SK, Kumaresan K, Venkateswarlu J, Pande G, Habibullah CM. (2010) Human fetal liver-derived stem cell transplantation as supportive modality in the management of end-stage decompensated liver cirrhosis. Cell Transplant. 19(4):409-18. ISSN 0963-6897

[40] Oertel M, Menthena A, Chen YQ, Teisner B, Jensen CH, Shafritz DA. (2008) Purification of fetal liver stem/progenitor cells containing all the repopulation potential for normal adult rat liver. Gastroenterology. 134(3):823-32 ISSN 0016-5085

[41] Abbasoglu O. (2008) Liver transplantation: yesterday, today and tomorrow. World J Gastroenterol. 14(20):3117-22. ISSN 1007-9327

[42] Gaudio E, Carpino G, Cardinale V, Franchitto A, Onori P, Alvaro D. (2009) New insights into liver stem cells. Dig Liver Dis. 41(7):455-62. ISSN 1590-8658

[43] Strom SC, Roy-Chowdhury J, Fox JI. (1999) Hepatocyte transplantation for the treatment of human disease. Sem Liver Dis 19: 39–48. ISSN 0272-8087.

[44] Allen KJ, Soriano H. (2001) Liver cell transplantation: The road to clinical application. J Lab Clin Med 138: 298–312. ISSN 0038-2299.

[45] Najimi M, Sokal E. (2004) Update on liver cell transplantation. J Pediatr Gastroenterol Nutr 39: 311–319. ISSN 0277-2299.

[46] Dhawan A, Mitry RR, Hughes RD. (2006) Hepatocyte transplantation for liver-based metabolic disorders. J Inherit Metab Dis 29: 431–435 ISSN 0141-8955.

[47] Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, Hovell C, Arthur MJ. (1998) Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest. 102(3):338-59. ISSN 0211-9738

[48] Dai L, Ji H, Kong UW, Zhang YH. (2010) Antifibrotic effects of ZK14, a novel nitric oxide-donating biphenyldicarboxylate derivative, on rat HSC-T6 cells and CCl4-induced hepatic fibrosis. Acta Pharmacol Sin. 31(1):27-34. ISSN 1671-4083

[49] Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, Hovell C, Arthur MJ. (1998) Mechanisms of spontaneous resolution of rat liver fibrosis.
Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest. 102(3):538-549. ISSN 0021-9738

[50] Wright MC, Issa R, Smart DE, Trim N, Murray GI, Primrose JN, Arthur MJ, Iredale JP, Mann DA. (2001) Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology. 121(3):685-698. ISSN 0016-5085

[51] Issa R, Williams E, Trim N, Kendall T, Arthur MJ, Reichen J, Benyon RC, Iredale JP. (2001) Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut. 48(4):548-557. ISSN 0017-5749

[52] Hartland SN, Murphy F, Aucott RL, Abercrombie A, Zhou X, Waung J, Patel N, Bradshaw C, Collins J, Mann D, Benyon RC, Iredale JP. (2009) Active matrix metalloproteinase-2 promotes apoptosis of hepatic stellate cells via the cleavage of cellular N-cadherin. Liver Int. 29(7):966-78. ISSN 1478-3223

[53] Leroy V, Monier F, Bottari S, Trocme C, Sturm N, Hilleret MN, Morel F, Zarski JP. (2004) Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol. 99(2):271-9. ISSN 0002-9270

[54] Issa R, Zhou X, Trim N, Millward-Sadler H, Krane S, Benyon C, Iredale J. (2003) Mutation in collagen-1 that confers resistance to the action of collagenase results in failure of recovery from CCl4-induced liver fibrosis, persistence of activated hepatic stellate cells, and diminished hepatocyte regeneration. FASEB J. 17(1):47-9. ISSN 0892-6638

[55] Cameron GR, Karunaratne WAE. (1936) Carbon tetrachloride cirrhosis in relation to liver regeneration. J Path Bact 42: 1-21, 0368-3494.

[56] Quinn PS, Higginson J. (1965) Reversible and irreversible changes in experimental cirrhosis. Am J Pathol 47: 353-369. ISSN 0002-9440

[57] Morrione TG, Levine J: Collagenolytic activity and collagen resorption in experimental cirrhosis. Arch Pathol 1967; 84: 59-63, 0363-0153.

[58] Hutterer F, Rubin E, Popper H. (1964) Mechanism of collagen resorption in reversible hepatic fibrosis. Exp Mol Pathol 86: 215-223 ISSN 0014-4800

[59] Takada A, Forta EA, Hartroft WS. (1967) The recovery of experimental dietary cirrhosis. Am J Pathol 51: 929-957, 0002-9440.

[60] Jacques WE, McAdams AI. (1957) Reversible biliary cirrhosis in rat after partial ligation of common bile duct. AMA Arch Path 63:149-153, ISSN 0096-6711.

[61] Okazaki I, Oda M, Maruyama K, Funatsu reversible biliary cirrhosis in rat after partial ligation of common bile duct. AMA Arch Path 63: 149-153 K, Matsuzaki S, Kamegaya K, Tsuchiya M. (1974) Mechanism of collagen resorption in experimental hepatic fibrosis with special reference to the activity of lysosomal enzymes. Biochem Exp Biol 11: 15-28, 0366-0060.

[62] Rubin E, Hutterer F: Hepatic fibrosis. (1967) Studies in the formation and resorption. In: Wagner BM, Smith DE, eds, The Connective Tissue, Baltimore, Williams and Wilkins, 142-160

[63] Perez-Tamayo R. (1965) Some aspects of connective tissue of the liver. In: Popper H, Schaffner F, eds, Progress in Liver Diseases 2, New York, Grune & Stratton, 192-210

[64] Rojkind M, Dunn MA. (1979) Hepatic fibrosis. Gastroenterology 76: 849-863, ISSN 0016-5085.
Maruyama K, Okazaki I, Kashiwazaki K, Oda M, Ishii H, Tsuchiya M. (1981) A case of subacute hepatitis with reversible liver fibrosis. Gastroenterol Jpn 16: 611-615, ISSN 0435-1339.

Arai M, Nioka M, Maruyama K, Wada N, Fujimoto N, Nomiyama T, Tanaka S, Okazaki I. (1996) Changes in serum levels of metalloproteinases and their inhibitors by treatment of chronic hepatitis C with interferon. Dig Dis Sci 41: 995-1000, ISSN 0163-2116.

Guettier C. (2005) Which stem cells for adult liver? Ann Pathol. 25(1):33-44, ISSN 0242-6498.

Shackel N, Rockey D. (2005) In pursuit of the "Holy Grail"—stem cells, hepatic injury, fibrogenesis and repair. Hepatology 41: 16–18, ISSN 0270-9139.

Vieyra DS, Jackson KA, Goodell MA. (2005) Plasticity and tissue regenerative potential of bone marrow-derived cells. Stem Cell Rev. 1: 65-69, ISSN 1550-8943.

Filip S, English D, Mokry J. (2004) Issues in stem cell plasticity. J. Cell. Mol. Med. 8: 572-7, ISSN 1582-1838.

Smart N, Riley PR. (2008) The stem cell movement. Circ Res. 102(10):1155-68, ISSN 0009-7330.

Eckersley-Maslin MA, Warner FJ, Grzelak CA, McCaughan GW, Shackel NA. (2009) Bone marrow stem cells and the liver: are they relevant? J Gastroenterol Hepatol. 24(10):1608-16, ISSN 0815-9316.

Oertel M, Menthena A, Chen YQ, Teisner B, Jensen CH, Shafritz DA. (2008) Purification of fetal liver stem/progenitor cells containing all the repopulation potential for normal adult rat liver. Gastroenterology. 134(3):823-832, ISSN 0016-5085.

Zhao Q, Ren H, Li X, Chen Z, Zhang X, Gong W, Liu Y, Pang T and Han ZC. (2009) Differentiation of human umbilical cord mesenchymal stromal cells into low immunogenic hepatocyte-like cells. Cytotherapy 11(4):414-426, ISSN 1465-3249.

Weiss ML, Medicetty S, Bledsoe AR, Rachakatla RS, Choi M, Merchav S, Luo Y, Rao MS, Velagaleti G, Troyer D. (2006) Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson’s disease. Stem Cells 24: 781 – 92. ISSN 0250-6793.

Medicetty S, Bledsoe AR, Fahrenholtz CB, Troyer D, Weiss ML. (2004) Transplantation of pig stem cells into rat brain: proliferation during the first 8 weeks. Exp Neurol 190: 32 – 41, ISSN 0014-4886.

Fu YS, Cheng YC, Lin MY, Cheng H, Chu PM, Chou SC, Shih YH, Ko MH, Sung MS. (2006) Conversion of human umbilical cord mesenchymal stem cells in Wharton’s jelly to dopaminergic neurons in vitro : potential therapeutic application for parkinsonism. Stem Cells 24: 115 – 124. ISSN 0250-6793.

Kögler G, Sensken S, Airey JA, Trapp T, Müschen M, Feldhahn N, Liedtke S, Sorg RV, Fischer J, Rosenbaum C, Greschat S, Knipper A, Bender J, Degistirici O, Gao J, Caplan AI, Colletti EJ, Almeida-Porada G, Müller HW, Zanjani E, Wernet P. (2004) A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med 200:123-135, ISSN 0022-1007.

Strauer BE, Brehm M, Zeus T, Bartsch T, Schannwell C, Antke C, Sorg RV, Kögler G, Wernet P, Müller HW, Köstering M. (2005) Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: IACT study. J Am Coll Cardiol 46:1651-1658, ISSN 0735-1097.
[80] Yoo KJ, Li RK, Weisel RD, Mickle DA, Jia ZQ, Kim EJ, Tomita S, Yau TM. (2000) Heart cell transplantation improves heart function in dilated cardiomyopathic hamsters. Circulation 102:III204-III209, ISSN 0009-7322.

[81] Kim SW, Han H, Chae GT, Lee SH, Bo S, Yoon JH, Lee YS, Lee KS, Park HK, Kang KS. (2006) Successful stem cell therapy using umbilical cord blood-derived multipotent stem cells for Buerger's disease and ischemic limb disease animal model. Stem Cells 24:1620-1626, ISSN 0220-6793.

[82] Lim JH, Byeon YE, Ryu HH, Jeong YH, Lee YW, Kim WH, Kang KS, Kweon OK. (2007) Transplantation of canine umbilical cord blood-derived mesenchymal stem cells in experimentally induced spinal cord injured dogs. J Vet Sci 8:275-282, ISSN 1229-845X

[83] Min JY, Yang Y, Sullivan MF, Ke Q, Converse KL, Chen Y, Morgan JP, Xiao YF. (2003) Long-term improvement of cardiac function in rats after infarction by transplantation of embryonic stem cells. Thorac Cardiovasc Surg 125:361-369. ISSN 0022-5223.

[84] Gordon MY, Gordon-Smith EC. (1981) Bone marrow fibroblastoid colony-forming cells (F-CFC) in aplastic anaemia: colony growth and stimulation of granulocyte-macrophage colony-forming cells (GM-CFC). Br J Haematol. 49(3):465-77, ISSN 0006-0291.

[85] Kadivar M, Khatami S, Mortazavi Y, Shokrgozar MA, Taghikhani M, Soleimani M. (2006) In vitro cardiomyogenic potential of human umbilical vein-derived mesenchymal stem cells. Biochem Biophys Res Commun. 340(2):639-47, ISSN 0006-291X

[86] Reinecke H, Minami E, Zhu WZ, Laflamme MA. (2008) Cardiogenic differentiation and transdifferentiation of progenitor cells. Circ Res. 103(10):1058-71, ISSN 0009-7330.

[87] Mishra PK, Singh SR, Joshua IG, Tyagi SC. (2010) Stem cells as a therapeutic target for diabetes. Front Biosci. 15:461-77, ISSN 1945-0494.

[88] Toyoda M, Cui Ch, Umezawa A. (2007) Myogenic transdifferentiation of menstrual blood-derived cells. Acta Myol. 26(3):176-178, ISSN 1128-2460.

[89] Bussolati B, Camussi G. (2007) Stem cells in acute kidney injury. Contrib Nephrol. 156:250-258, ISSN 0302-5114.

[90] Bahk JY, Jung JH, Han H, Min SK, Lee YS. (2010) Treatment of diabetic impotence with umbilical cord blood stem cell intracavernosal transplant: preliminary report of 7 cases. Exp Clin Transplant. 8(2):150-60, ISSN 1304-0855.

[91] Nikeghbalian S, Pournasr B, Aghdami N, Rasekh A, Geramizadeh B, Hosseini Asl SM, Ramzi M, Kakaee F, Namiri M, Malekzadeh R, Vosough Dizaj A, Malek-Hosseini SA, Baharvand H. (2011) Autologous transplantation of bone marrow-derived mononuclear and CD133(+) cells in patients with decompensated cirrhosis. Arch Iran Med. 14(1):12-7, ISSN 1029-2977.

[92] Ren C, Kumar S, Chanda D, Kallman L, Chen J, Mountz JD, Ponnazhagan S. (2008) Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model. Gene Ther. 15(21):1446-53, ISSN 0969-7128.

[93] Dan YY, Yeoh GC. (2008) Liver stem cells: a scientific and clinical perspective. J Gastroenterol Hepatol. 23(5):687-698, ISSN 0815-9319.

[94] Thomson JA, Kalishman J, Golos TG, Durning M, Harris CP, Becker RA, Hearn JP. (1995) Isolation of a primate embryonic stem cell line. Proc Natl Acad Sci U S A. 92(17):7844-8, ISSN 0027-8424.
[95] Takahashi K, Yamanaka S. (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 126(4):663-76, ISSN 0062-8674.

[96] Yoshimura K, Sato K, Aoi N, Kurita M, Inoue K, Suga H, Eto H, Kato H, Hiroi T, Harii K. (2008) Cell-assisted lipotransfer for facial lipoatrophy: efficacy of clinical use of adipose-derived stem cells. Dermatol Surg. 34(9):1178-85, ISSN 1076-0512.

[97] Alvarez-Buylla A, Lois C. (1995) Neuronal stem cells in the brain of adult vertebrates. Stem Cells. 13(3):263-72, ISSN 0220-6793.

[98] Ohyama M. (2007) Hair follicle bulge: A fascinating reservoir of epithelial stem cells. J Dermatol Surg. 34(9):1178-85, ISSN 1076-0512.

[99] van der Bogt KEA, Sheikh AY, Schrepfer S, Hoyt G, Cao F, Ransohoff KJ, Swijnenburg J, Pearl J, Lee A, Fischbein M, Contag CH, Wu JC. (2008) Comparison of Different Adult Stem Cell Types for Treatment of Myocardial Ischemia. Circulation 118:S121-S129, ISSN 0009-7322.

[100] Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, Esperou H, Thierry D, Socie G, Lehn, P. (1999) Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA identical sibling. N Engl J Med., 321(17), 1174-1178, ISSN 0028-4793.

[101] Reffelmann T, Koenemann S, Kloner RA. (2009) Promise of blood- and bone marrow- derived stem cell transplantation for functional cardiac repair: putting it in perspective with existing therapy. J Am Coll Cardiol 53: 1055, ISSN 0735-1097.

[102] Zhang QH, She MP. (2007) Biological behaviour and role of endothelial progenitor cells in vascular diseases. Chin Med J (Engl). 120:2297, ISSN 0366-6999.
marrow stromal cells and cultured in a flow perfusion bioreactor. Tissue Eng. 12(1):177-88, ISSN 1076-3279.

[112] Lee MY, Huang JP, Chen YY, Aplin JD, Wu YH, Chen CY, Chen PC, Chen CP. (2009) Angiogenesis in differentiated placental multipotent mesenchymal stromal cells is dependent on integrin alpha5beta1. PLoS One. 22;4(10):e6913, ISSN 1392-6203.

[113] Fan CG, Zhang QJ, Tang FW, Han ZB, Wang GS, Han ZC. (2005) Human umbilical cord blood cells express neurotrophic factors. Neurosci Lett. 3:380(3):322-5, ISSN 0304-3940.

[114] Youssoufian M, Walmsley B. (2007) Brain-derived neurotrophic factor modulates cell excitability in the mouse medial nucleus of the trapezoid body. Eur J Neurosci. 25(6):1647-52, ISSN 0953-816X.

[115] Eton D, Yu H. (2010) Enhanced cell therapy strategy to treat chronic limb-threatening ischemia. J Vasc Surg. 52(1):199-204, ISSN 0741-5214.

[116] Chang SA, Kang HJ, Lee HY, Kim KH, Hur J, Han KS, Park YB, Kim HS. (2009) Peripheral blood stem cell mobilisation by granulocyte-colony stimulating factor in patients with acute and old myocardial infarction for intracoronary cell infusion. Heart. 95(16):1326-30, ISSN 1355-6037.

[117] Kang HJ, Kim HS. (2008) G-CSF- and erythropoietin-based cell therapy: a promising strategy for angiomyogenesis in myocardial infarction. Expert Rev Cardiovasc Ther. 6(5):703-13, ISSN 1477-9072.

[118] Savitz SI, Chopp M, Deans R, Carmichael ST, Phinney D, Wechsler L. (2011) Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II. Stroke. 42(3):825-9, ISSN 0039-2499.

[119] Urbaniak Hunter K, Yarbrough C, Ciacci J. (2010) Gene- and cell-based approaches for neurodegenerative disease. Adv Exp Med Biol. 671:117-30, ISSN 0065-2598.

[120] Lee HJ, Lee JK, Lee H, Shin JW, Carter JE, Sakamoto T, Jin HK, Bae JS. (2010) The therapeutic potential of human umbilical cord blood-derived mesenchymal stem cells in Alzheimer's disease. Neurosci Lett. 30;481(1):30-5, ISSN 0304-3940.

[121] Fornai F, Meininger V, Silani V. (2011) Future therapeutic strategies dictated by preclinical evidence in ALS. Arch Ital Biol. 149(1):169-74, ISSN 0003-9829.

[122] Ramachandran P, Iredale JP. (2009) Reversibility of liver fibrosis. Ann Hepatol. 8(4):283-91, ISSN 1665-2681.

[123] Durante AJ, St Louis T, Meek JJ, Navarro VJ, Sofair AN. (2008) The mortality burden of chronic liver disease may be substantially underestimated in the United States. Conn Med. 72(7):389-92, ISSN 0011-6178.

[124] Hui AY, Friedman SL. (2003) Molecular basis of hepatic fibrosis. Expert Rev Mol Med. 5(5):1-23, ISSN 1462-3994.

[125] Li JT, Liao ZK, Ping J, Xu D, Wang H. (2008) Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies. J Gastroenterol. 43(6):419-28, ISSN 0944-1774.

[126] Friedman SL. (1999) Cytokines and fibrogenesis. Semin Liver Dis. 19(2):129-40, ISSN 0272-8087.

[127] Han YP. (2006) Matrix metalloproteinases, the pros and cons, in liver fibrosis. J Gastroenterol Hepatol. 21 Suppl 3:S88-91, ISSN 0815-9319.

[128] Hartland SN, Murphy FL, Abergel A, Zhou X, Waung J, Patel N, Bradshaw C, Collins J, Mann D, Benyon RC, Iredale JP. (2009) Active matrix metalloproteinase-2 promotes apoptosis of hepatic stellate cells via the cleavage of cellular N-cadherin. Liver Int. 29(7):966-78, ISSN 1478-3223.
[129] Povero D, Busletta C, Novo E, di Bonzo LV, Cannito S, Patronostro C, Parola M. (2010) Liver fibrosis: a dynamic and potentially reversible process. Histol Histopathol. 25(8):1075-91, ISSN 0213-3911.

[130] Cantz T, Sharma AD, Jocheim-Richter A, Arseniev L, Klein C, Manns MP, Ott M. (2004) Reevaluation of bone marrow-derived cells as a source for hepatocyte regeneration. Cell Transplant. 13(6):659-66, ISSN 0963-6897.

[131] Friedman SL. (1999) Cytokines and fibrogenesis. Semin Liver Dis. 19(2):129-40, ISSN 0272-8087.

[132] Jiang JX, Venugopal S, Serizawa N, Chen X, Scott F, Li Y, Adamson R, Devaraj S, Shah V, Gershwin ME, Friedman SL, Török NJ. (2010) Reduced nicotinamide adenine dinucleotide phosphate oxidase 2 plays a key role in stellate cell activation and liver fibrogenesis in vivo. Gastroenterology. 139(4):1375-84. 0016-5085.

[133] Myung SJ, Yoon JH, Kim BH, Lee JH, Jung EU, Lee HS. (2009) Heat shock protein 90 inhibitor induces apoptosis and attenuates activation of hepatic stellate cells. J Pharmacol Exp Ther. 330(1):276-282, ISSN 0022-3565.

[134] Han YP. (2006) Matrix metalloproteinases, the pros and cons, in liver fibrosis. J Gastroenterol Hepatol. 21 Suppl 3:888-91, ISSN 0815-9319.

[135] Langer DA, Das A, Semela D, Kang-Decker N, Hendrickson H, Bronk SF, Katusic ZS, Gores GJ, Shah VH. (2008) Nitric oxide promotes caspase-independent hepatic stellate cell apoptosis through the generation of reactive oxygen species. Hepatology. 47(6):1983-93, ISSN 0270-9139.

[136] Liu Y, Wen XM, Lui EL, Friedman SL, Cui W, Ho NP, Li L, Ye T, Fan ST, Zhang H. (2009) Therapeutic targeting of the PDGF and TGF-beta-signaling pathways in hepatic stellate cells by PTK787/ZK22258. Lab Invest. 89(10):1152-60, ISSN 0023-6837.

[137] Gonzalo T, Beljaars L, van de Boovenkamp M, Temming K, van Loenen AM, Reker-Smit C, Meijer DK, Lacombe M, Opdam F, Kéri G, Orfi L, Poelstra K, Kok RJ. (2007) Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells. J Pharmacol Exp Ther. 321(3):856-65, ISSN 0022-3565.

[138] Yoshiji H, Noguchi R, Kuriyama S, Ikenaka Y, Yoshii J, Yanase K, Namisaki T, Kitade M, Masaki T, Fukui H. (2005) Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am J Physiol Gastrointest Liver Physiol. 288(5):G907-13, ISSN 0193-1857.

[139] Hartland SN, Murphy F, Aucott RL, Abergel A, Zhou H, Waung J, Patel N, Bradshaw C, Collins J, Mann D, Benyon RC, Iredale JP. (2009) Active matrix metalloproteinase-2 promotes apoptosis of hepatic stellate cells via the cleavage of cellular N-cadherin. J Exp Med. 203:1327-34, ISSN 0022-1000. 10.1084/jem.20090136.

[140] Talbot V, Mallat A, Gallois C, Belmadani S, Méry PF, Nhieu JT, Pavoine C, Lotersztajn S. (1999) Biological effects of C-type natriuretic peptide in human myofibroblastic hepatic stellate cells. J Biol Chem. 20;274(34):23761-9, ISSN 0021-9258.

[141] Povero D, Busletta C, Novo E, di Bonzo LV, Cannito S, Patronostro C, Parola M. (2010) Liver fibrosis: a dynamic and potentially reversible process. Histol Histopathol. 25(8):1075-91, ISSN 0213-3911.

www.intechopen.com
[143] Cantz T, Sharma AD, Jochheim-Richter A, Arseniev L, Klein C, Manns MP, Ott M. (2004) Reevaluation of bone marrow-derived cells as a source for hepatocyte regeneration. Cell Transplant. 13(6):659-66, ISSN 0963-6897.

[144] Kharaziha P, Hellstroem PM, Noorinayerb B, Farzanehd F, Aghajanib K, Jafarib F, Telkabadib M, Atashid A, Honardoostd M, Zalic MR and Soleimanie M. (2009) Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I–II clinical trial. Eur J Gastroenterol Hepatol 21:1199–1205, ISSN 0954-691X

[145] Shackel N, Rockey D. (2005) In pursuit of the “Holy Grail”—stem cells, hepatic injury, fibrogenesis and repair. Hepatology 41: 16-18, ISSN 0279-9139.

[146] Jensen CH, Jauho EI, Santoni-Rugiu E, Holmsovk U, Teisner B, Tygstrup N, Bisgaard HC. (2004) Transit-amplifying ductular (oval) cells and their hepatocytic progeny are characterized by a novel and distinctive expression of delta-like protein/ preadipocyte factor 1/fetal antigen 1. Am. J. Pathol. 164: 1347–1359. ISSN 0002-9440.

[147] Khurana S, Mukhopadhyay A. (2007) Characterization of the potential subpopulation of bone marrow cells involved in the repair of injured liver tissue. Stem Cells 25: 1439–47, ISSN 0250-6793.

[148] Stenderup K, Justesen J, Clausen C, Kassem M. (2003) Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone. 33:919–26. ISSN 8756-3282.

[149] Mueller SM, Glowacki J. (2001) Age-related decline in the osteogenic potential of human bone marrow cells cultured in three-dimensional collagen sponges. J Cell Biochem. 82:583–90, ISSN 0730-2312.

[150] Zhong YS, Lin N, Deng MH, Zhang FC, Tang ZF, Xu RY. (2010) Deficient proliferation of bone marrow-derived mesenchymal stem cells in patients with chronic hepatitis B viral infections and cirrhosis of the liver. Dig Dis Sci. 55(2):438-45. ISSN 0163-9440.

[151] Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. (2001) Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng 7:211–228. ISSN 1937-3341.

[152] Lee RH, Kim B, Choi I, Kim H, Choi HS, Suh K, Bae YC, Jung JS. (2004) Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue. Cell Physiol Biochem 14:311–324. ISSN 1015-8987

[153] Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, Ortega J, Souillet G, Ferreira E, Laporte JP, Fernandez M, Chastang C. (1997) Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med. 337:573–81, ISSN 0028-4793.

[154] Grewal SS, Barker JN, Davies SM, Wagner JE. (2003) Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood. Blood. 101:4233–44, ISSN 0006-4971.

[155] Warkentin PI. (2003) Foundation for the Accreditation of Cellular Therapy Voluntary accreditation of cellular therapies: Foundation for the Accreditation of Cellular Therapy (FACT) Cytotherapy. 5:299–305, ISSN 1465-3249.

[156] Chen MY, Lie PC, Li ZL, Wei X. (2009) Endothelial differentiation of Wharton's jelly-derived mesenchymal stem cells in comparison with bone marrow-derived mesenchymal stem cells. Exp Hematol. 37(5):629-40, ISSN 0301-482X.
[157] Zhong YS, Lin N, Deng MH, Zhang FC, Tang ZF, Xu RY. (2010) Deficient proliferation of bone marrow-derived mesenchymal stem cells in patients with chronic hepatitis B viral infections and cirrhosis of the liver. Dig Dis Sci. 55(2):438-45, ISSN 0163-2116.

[158] Moriya K, Yoshikawa M, Ouij Y, Saito K, Nishiofuku M, Matsuda R, Ishizaka S, Fukui H. (2008) Embryonic stem cells reduce liver fibrosis in CCl4-treated mice. Int J Exp Pathol. 89(6):401-9, ISSN 0959-9673.

[159] Liu P, Liu ZD, Wu N, cong X, Fei R, Chen HS, Wei L. (2009) Transplanted Endothelial Progenitor Cells Ameliorate Carbon Tetrachloride–Induced Liver Cirrhosis in Rats. Liver Transpl 15:1092-1100, ISSN 1527-6465.

[160] Yan Y, Xu W, Qian H, Si Y, Zhu W, Cao H, Zhou H, Mao F. (2009) Mesenchymal stem cells from human umbilical cords ameliorate mouse hepatic injury in vivo. Liver Int. 29(3):356-65, ISSN 1478-4223.

[161] Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, Bagheri M, Bashtar M, Ghanaati H, Baharvand H, Ghavamzadeh A, Malekzadeh R. (2007) Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med. 10(4):459-66, ISSN 1029-2977.

[162] Li M, Yu J, Li Y, Li D, Yan D, Qu Z, Ruan Q. (2010) CXCR4 positive bone mesenchymal stem cells migrate to human endothelial cell stimulated by ox-LDL via SDF-1alpha/CXCR4 signaling axis. Exp Mol Pathol. 88(2):250-5, ISSN 0014-4800.

[163] Magnasco A, Corselli M, Bertelli R, Ibitici A, Peresi M, Gaggero G, Cappiello V, Chiavarina B, Mattioli G, Gusmano R, Ravetti JL, Frassoni F, Ghiggeri GM. (2008) Mesenchymal stem cells protective effect in adriamycin model of nephropathy. Cell Transplant. 17(10-11):1157-67, ISSN 0963-6897.

[164] Zhao X, Huang L, Yin Y, Fang Y, Zhou Y. (2007) Autologous endothelial progenitor cells transplantation promoting endothelial recovery in mice. Transpl Int. 20(8):712-21, ISSN 0943-0874.

[165] Di Campli C, Piscaglia AC, Rutella S, Bonanno G, Vecchio FM, Zocco MA, Monego G, Michetti F, Mancuso S, Pola P, Leone G, Gasbarrini G, Gasbarrini A. (2005) Improvement of mortality rate and decrease in histologic hepatic injury after human cord blood stem cell infusion in a murine model of hepatotoxicity. Transplant Proc. 37(6):2707-10, ISSN 0041-1345.

[166] Okura H, Saga A, Fumimoto Y, Soeda M, Moriyama M, Moriyama H, Nagai K, Lee CM, Yamashita S, Ichinose A, Hayakawa T, Matsuyama A. (2011) Transplantation of human adipose tissue-derived multilineage progenitor cells reduces serum cholesterol in hyperlipidemic watanabe rabbits. Tissue Eng Part C Methods. 17(2):145-54, ISSN 1937-3384.

[167] Kang HJ, Kim MK, Kim MG, Choi DJ, Yoon JH, Park YB, Kim HS. (2011) A multicenter, prospective, randomized, controlled trial evaluating the safety and efficacy of intracoronary cell infusion mobilized with granulocyte colony-stimulating factor and darbepoetin after acute myocardial infarction: study design and rationale of the 'MAGIC cell-5-combination cytokine trial'. Trials. 7;12(1):33, ISSN 1745-6215.

[168] Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB Jr, Reisman MA, Schaeer GL, Sherman W. (2009) A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 54(24):2277-86, ISSN 0735-1097.
Chang SA, Kang HJ, Lee HY, Kim KH, Hur J, Han KS, Park YB, Kim HS. (2009) Peripheral blood stem cell mobilisation by granulocyte-colony stimulating factor in patients with acute and old myocardial infarction for intracoronary cell infusion. Heart. 95(16):1326-30, ISSN 1335-6037.

Zohlnhöfer D, Dibra A, Koppara T, de Waha A, Ripa RS, Kastrup J, Valgimigli M, Schömig A, Kastrati A. (2008) Stem cell mobilization by granulocyte colony-stimulating factor for myocardial recovery after acute myocardial infarction: a meta-analysis. J Am Coll Cardiol. 51(15):1429-37, ISSN 0735-1097.

Fan L, Chen L, Chen X, Fu F. (2008) A meta-analysis of stem cell mobilization by granulocyte colony-stimulating factor in the treatment of acute myocardial infarction. Cardiovasc Drugs Ther. 22(1):45-54, ISSN 0920-3206.

Zhang S, Sun A, Xu D, Yao K, Huang Z, Jin H, Wang K, Zou Y, Ge J. (2009) Impact of timing on efficacy and safety of intracoronary autologous bone marrow stem cells transplantation in acute myocardial infarction: a pooled subgroup analysis of randomized controlled trials. Clin Cardiol. 32(8):458-66, ISSN 0160-9289.

Sun L, Zhang T, Lan X, Du G. (2010) Effects of stem cell therapy on left ventricular remodeling after acute myocardial infarction: a meta-analysis. Clin Cardiol. 33(5):296-302, ISSN 0160-9289.

Pendharkar AV, Chua JY, Andres RH, Wang N, Gaeta X, Wang H, De A, Choi R, Chen S, Rutt BK, Gambhir SS, Guzman R. (2010) Biodistribution of neural stem cells after intravascular therapy for hypoxic-ischemia. Stroke. 41(9):2064-70, ISSN 0093-2499.

Harting MT, Jimenez F, Xue H, Fischer UM, Baumgartner J, Dash PK, Cox CS. (2009) Intraosseous mesenchymal stem cell therapy for traumatic brain injury. J Neurosurg. 110(6):1189-97, ISSN 0022-3085.

Feng Q, Chow PK, Frassoni F, Phua CM, Tan PK, Prasath A, Khee Hwang WY. (2008) Nonhuman primate allogeneic hematopoietic stem cell transplantation by intravenous injection: Engraftment, donor cell distribution, and mechanistic basis. Exp Hematol. 36(11):1556-66, ISSN 0301-472X.

Hohenstein B, Kuo MC, Addabbo F, Yasuda K, Ratliff B, Schwarzenberger C, Eckardt KD, Hugo CP, Goligorsky MS. (2010) Enhanced progenitor cell recruitment and endothelial repair after selective endothelial injury of the mouse kidney. Am J Physiol Renal Physiol. 298(6):F1504-14, ISSN 1931-857X.

Herrmann JL, Abarbanell AM, Weil BR, Wang Y, Poynter JA, Manukyan MC, Meldrum DR. (2010) Postinfarct intramyocardial injection of mesenchymal stem cells pretreated with TGF-alpha improves acute myocardial function. Am J Physiol Regul Integr Comp Physiol. 299(1):R371-8, ISSN 0363-6119.

Kögler G, Radke TF, Lefort A, Sensken S, Fischer J, Sorg RV, Wernet P. (2005) Cytokine production and hematopoiesis supporting activity of cord blood-derived unrestricted somatic stem cells. Exp Hematol. 33(5):573-83, ISSN 0301-472X.

Liu CH, Hwang SM. (2005) Cytokine interactions in mesenchymal stem cells from cord blood. Cytokine. 32(6):270-279, ISSN 1014-4666.

Gak E, Taylor WG, Chan AM, Rubin JS. (1992) Processing of hepatocyte growth factor to the heterodimeric form is required for biological activity. FEBS Lett. 311(1):17-21, ISSN 0014-5793.

Nakamura T, Nawa K, Ichihara A. (1984) Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 122:1450-1459, ISSN 0006-291X.
[183] Nakamura T, Nishizawa T, Hagiy M, Seki T, Shimoniishi M, Sugimura A, Tashiro K, Shimizu S. (1989) Molecular cloning and expression of human hepatocyte growth factor. Nature 342:440-443, ISSN 0028-0836.

[184] Kim WH, Matsumoto K, Bessho K, Nakamura T. (2005) Growth inhibition and apoptosis in liver myofibrolasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis. Am J Pathol 161:1017-1028, ISSN 0002-9440.

[185] Yu Y, Lu L, Qian X, Chen N, Yao A, Pu L, Zhang F, Li X, Kong L, Sun B, Wang X. (2010) Antifibrotic effect of hepatocyte growth factor-expressing mesenchymal stem cells in small-for-size liver transplant rats. Stem Cells Dev. 19(6):903-14, ISSN 1547-3287.

[186] Chang YJ, Liu JW, Lin PC, Sun LY, Peng CW, Luo GH, Chen TM, Lee RP, Lin SZ, Harn HJ, Chiou TW. (2009) Mesenchymal stem cells facilitate recovery from chemically induced liver damage and decrease liver fibrosis. Life Sci. 85(13-14):517-25, ISSN 0024-3205.

[187] Tanabe J, Izawa A, Takemi N, Miyauchi Y, Torii Y, Tsuchiya H, Suzuki T, Sone S, Ando K. (2007) Interferon-beta reduces the mouse liver fibrosis induced by repeated administration of concanavalin A via the direct and indirect effects. Immunology. 122(4):562-70, ISSN 0019-2805.

[188] Tasci I, Mas MR, Vural SA, Comert B, Alcigir G, Serdar M, Mas N, Isik AT, Ates Y. (2006) Rat liver fibrosis regresses better with pegylated interferon alpha2b and ursodeoxycholic acid treatments than spontaneous recovery. Liver Int 26:261–268, ISSN 1478-3223.

[189] Block ET, Cronstein BN. (2010) Interferon-gamma inhibits adenosine A2A receptor function in hepatic stellate cells by STAT1-mediated repression of adenylyl cyclase. Int J Interferon Cytokine Mediator Res. 2010(2):113-126, ISSN 1179-139X.

[190] Jones JI, Clemmons DR. (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 16:3–32, ISSN 0163-769X.

[191] Clemmons DR, Van Wyk JJ. (1984) Factors controlling blood concentration of somatomedin C. Clin Endocrinol Metab 13:113-43, ISSN 0300-595X.

[192] Conchillo M, de Knegt RJ, Payeras M, Quiroga J, Sangro B, Herrero JL, Castilla-Cortazar I, Frystyk J, Flyvbjerg A, Yoshizawa C, Jansen PL, Scharschmidt B, Prieto J. (2005) Insulin-like growth factor I(IGF-1) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol 43:630-636. ISSN 0168-8278.

[193] Caro JF, Poulois J, Ittoop O, Pories WJ, Flickinger EG, Sinha MK. (1988) Insulin like growth factor I binding in hepatocytes from human liver, heman hepatoma, and normal, regenerating, and fetal rat liver. J Clin Invest 81:976-981. ISSN 0021-9738.

[194] Scharf JG, Knittel T, Dombrowski F, Müller L, Saile B, Braulke T, Hartmann H, Ramadori G. (1998) Characterization of the IGF axis components in isolate rat hepatic stellate cells. Hepatology 27:1275-1284. ISSN 0270-9139.

[195] Sobrevals L, Rodriguez C, Romero-Trevejo JL, Gondi G, Monreal I, Pañeda A, Juanarena N, Arcelus S, Razquin N, Guembe L, Gonzalez-Aseguinolaza G, Prieto J, Fortes P. (2010) Insulin-like growth factor I gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats. Hepatology. 51(3):912-21. ISSN 0270-9139.

[196] Tutau F, Rodriguez-Ortigosa C, Puche JE, Juanarena N, Monreal I, García Fernández M, Clavijo E, Castilla A, Castilla-Cortazar I. (2009) Enhanced actions of insulin-like growth factor-I and interferon-alpha co-administration in experimental cirrhosis. Liver Int. 29(1):37-46. ISSN 1478-3223.

www.intechopen.com
[197] Gilchrist ES, Plevris JN. (2010) Bone Marrow-Derived Stem Cells in Liver Repair: 10 Years Down the Line. Liver Transpl 16:118-129. ISSN 1527-6465.

[198] Kögl G, Radke TF, Lefort A, Sensken S, Fischer J, Sorg RV, Wernet P. (2005) Cytokine production and hematopoiesis supporting activity of cord blood-derived unrestricted somatic stem cells. Exp Hematol. 33(5):573-83. ISSN 0301-472X.

[199] Schibler KR, Liechty KW, White WL, Christensen RD. (1993) Production of granulocyte colony-stimulating factor in vitro by monocytes from preterm and term neonates. Blood. 82(8):2478-84. ISSN 0006-4971.

[200] Jenhani F, Durand V, Ben Azouna N, Thallet S, Ben Othmen T, Bejaoui M, Domenech J. (2011) Human cytokine expression profile in various conditioned media for in vitro expansion bone marrow and umbilical cord blood immunophenotyped mesenchymal stem cells. Transplant Proc. 43(2):639-43. ISSN 0041-1345.

[201] Suehiro Y, Muta K, Umemura T, Abe Y, Nishimura J, Nawata H. (1999) Macrophage inflammatory protein 1alpha enhances in a different manner adhesion of hematopoietic progenitor cells from bone marrow, cord blood, and mobilized peripheral blood. Exp Hematol. 27(11):1637-45. ISSN 0301-472X.

[202] Liu CH, Hwang SM. (2005) Cytokine interactions in mesenchymal stem cells from cord blood. Cytokine. 32(6):270-9. ISSN 1043-4666.

[203] Gang EJ, Jeong JA, Han S, Yan Q, Jeon CJ, Kim H. (2006) In vitro endothelial potential of human UC blood-derived mesenchymal stem cells. Cytotherapy. 8(3):215-27. ISSN 1465-3249.

[204] Khan AA, Shaik MV, Parveen N, Rajendraprasad A, Aleem MA, Habeeb MA, Srinivas G, Raj TA, Tiwari SK, Kumaresan K, Venkateswarlu J, Pande G, Habibullah CM. (2010) Human fetal liver derived stem cell transplantation as supportive modality in the management of end-stage decompensated liver cirrhosis. Cell Transplant 19(4) 409-418. ISSN 0963-6897.
Based on our current understanding of cell biology and strong supporting evidence from previous experiences, different types of human stem cell populations are capable of undergoing differentiation or trans-differentiation into functionally and biologically active cells for use in therapeutic purposes. So far, progress regarding the use of both in vitro and in vivo regenerative medicine models already offers hope for the application of different types of stem cells as a powerful new therapeutic option to treat different diseases that were previously considered to be untreatable. Remarkable achievements in cell biology resulting in the isolation and characterization of various stem cells and progenitor cells has increased the expectation for the development of a new approach to the treatment of genetic and developmental human diseases. Due to the fact that currently stem cells and umbilical cord banks are so strictly defined and available, it seems that this mission is investigational more practical than in the past. On the other hand, studies performed on stem cells, targeting their conversion into functionally mature tissue, are not necessarily seeking to result in the clinical application of the differentiated cells; in fact, still one of the important goals of these studies is to get acquainted with the natural process of development of mature cells from their immature progenitors during the embryonic period onwards, which can produce valuable results as knowledge of the developmental processes during embryogenesis. For example, the cellular and molecular mechanisms leading to mature and adult cells developmental abnormalities are relatively unknown. This lack of understanding stems from the lack of a good model system to study cell development and differentiation. Hence, the knowledge reached through these studies can prove to be a breakthrough in preventing developmental disorders. Meanwhile, many researchers conduct these studies to understand the molecular and cellular basis of cancer development. The fact that cancer is one of the leading causes of death throughout the world, highlights the importance of these researches in the fields of biology and medicine.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:

Jong Yoon Bahk, Zhengfu Piao, Jae Hun Jung and Hoon Han (2011). Treatment of the End Stage Liver Cirrhosis by Human Umbilical Cord Blood Stem Cells: Preliminary Results, Stem Cells in Clinic and Research, Dr. Ali Gholamrezanezhad (Ed.), ISBN: 978-953-307-797-0, InTech, Available from: http://www.intechopen.com/books/stem-cells-in-clinic-and-research/treatment-of-the-end-stage-liver-cirrhosis-by-human-umbilical-cord-blood-stem-cells-preliminary-results
